Login
$SRRK
$44.54 +$1.34 (3.09%) Live

$SRRK SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
16 Nov 2026 SCHEDULE 13G/A
10 Nov 2026 10-Q
10 Nov 2026 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more

U.S. launch of ISEMBYLD™ (apitegromab-mstn), the first and only muscle-targeted therapy for children and adults living with spinal muscular atrophy (SMA), underway following September 11, 2026 FDA approval

27 Oct 2026 Form 4: Akkaraju Srinivas, Director

Bought 142,500 shares ($5.89M) · Bought 146,970 shares ($6.11M)

01 Oct 2026 144
25 Sep 2026 Form 4: Woods Keith, Chief Operating Officer

Gave 48,034 shares as a gift

23 Sep 2026 Form 4: Hallal David, Director

Gave 36,652 shares as a gift

15 Sep 2026 8-K: Regulation FD Disclosure

On September 14, 2026, Scholar Rock Holding Corporation (the “Company”) hosted a live audio webcast (the “Investor Call”) announcing that the U.S. Food and Drug Administration (“FDA”) has approved ISEMBYLD™ (apitegromab-mstn) for the tre...

14 Sep 2026 8-K: Regulation FD Disclosure; Other Events

Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)

14 Aug 2026 SCHEDULE 13G/A
13 Aug 2026 SCHEDULE 13G/A
06 Aug 2026 8-K: Other Events

Re: Securities Registered under Registration Statement on Form S-3ASR

06 Aug 2026 424B5
06 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

Apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA) review by FDA continues to advance with two fill-finish facilities, representing two independent paths to an FDA approval decision by September 30, 2026 Pr...

06 Jul 2026 Form 4: Flier Jeffrey S., Director

Sold 3,053 shares ($164K)

06 Jul 2026 Form 4: Gilman Michael, Director

Sold 2,544 shares ($137K)

06 Jul 2026 Form 4: Burow Kristina, Director

Sold 3,053 shares ($164K)

06 Jul 2026 Form 4: Reed Joshua, Director

Sold 3,053 shares ($164K)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support